Capricor Therapeutics (LTS:0HTB) Days Payable: 0.00 (As of Mar. 2026)

What is Capricor Therapeutics Days Payable?

Capricor Therapeutics LTS:0HTB 37 Days Payable is 0.00 as of Mar. 2026. GuruFocus rates LTS:0HTB with a GF Score™ of 37/100. The stock has 3 warning signs investors should review. Among 700 Biotechnology companies, Capricor Therapeutics ranks worse than 142857% on this metric.

Capricor Therapeutics's average Accounts Payable for the three months ended in Mar. 2026 was €2.41 Mil. Capricor Therapeutics's Cost of Goods Sold for the three months ended in Mar. 2026 was €0.00 Mil.

The historical rank and industry rank for Capricor Therapeutics's Days Payable or its related term are showing as below:

LTS:0HTB's Days Payable is not ranked ^*
in the Biotechnology industry.
Industry Median: 113.1
* Ranked among companies with meaningful Days Payable only.

Capricor Therapeutics's Days Payable stayed the same from Mar. 2025 (0.00) to Mar. 2026 (0.00). stayed the same

Capricor Therapeutics Days Payable Related Terms

Capricor Therapeutics Days Payable Historical Data

* Premium members only.

The historical data trend for Capricor Therapeutics's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Capricor Therapeutics Days Payable Chart

Capricor Therapeutics Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Dec25

Days Payable

Get a 7-Day Free Trial

0.00

Capricor Therapeutics Quarterly Data
	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24	Mar25	Jun25	Sep25	Dec25	Mar26
Days Payable	Get a 7-Day Free Trial															0.00	0.00	0.00	0.00	0.00

LTS:0HTB vs COAG, DMRA, MPLT: Days Payable Comparison

For the Biotechnology subindustry, Capricor Therapeutics's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Capricor Therapeutics Days Payable vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Capricor Therapeutics's Days Payable distribution charts can be found below:

* The bar in red indicates where Capricor Therapeutics's Days Payable falls into.

Save Embed

Capricor Therapeutics Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Capricor Therapeutics's Days Payable for the fiscal year that ended in Dec. 2025 is calculated as

	Days Payable (A: Dec. 2025 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2024 )	+	Accounts Payable (A: Dec. 2025 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2025 )	*	Days in Period
=	( (3.136	+	1.413)	/	2 )	/	0	*	365
=	2.2745					/	0	*	365
=	N/A

Capricor Therapeutics's Days Payable for the quarter that ended in Mar. 2026 is calculated as:

	Days Payable (Q: Mar. 2026 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Dec. 2025 )	+	Accounts Payable (Q: Mar. 2026 ))	/	count )	/	Cost of Goods Sold (Q: Mar. 2026 )	*	Days in Period
=	( (1.413	+	3.398)	/	2 )	/	0	*	365 / 4
=	2.4055					/	0	*	365 / 4
=	N/A

Frequently Asked Questions Learn more about Days Payable →

What does a Days Payable of 0.00 mean?

Capricor Therapeutics (LTS:0HTB) has a Days Payable of 0.00 as of Mar. 2026. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Capricor Therapeutics and its competitors. According to the industry distribution chart, Capricor Therapeutics ranks #999999 out of 700 companies in the Biotechnology industry.

Is Capricor Therapeutics' Days Payable too high?

Capricor Therapeutics' current Days Payable is 0.00. Based on the distribution chart, Capricor Therapeutics ranks #999999 out of 700 companies in the Biotechnology industry, which is in the bottom quartile relative to peers. Overall, Capricor Therapeutics has a GF Score™ of 37/100, reflecting its overall financial health beyond just this single metric.

How does Capricor Therapeutics' Days Payable compare to COAG and DMRA?

According to the Biotechnology industry distribution chart, Capricor Therapeutics ranks #999999 out of 700 companies for Days Payable. This places Capricor Therapeutics in the lower half of its industry. The industry median Days Payable is 113.10. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.

What is a good Days Payable for a Biotechnology company?

The median Days Payable among Biotechnology companies is 113.10, based on 700 companies in the industry. Companies in the top quartile (top 25%) have a Days Payable significantly above this median, while those in the bottom quartile fall well below. However, Days Payable should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.

What does a high Days Payable mean?

A high Days Payable can signal that a stock is expensive relative to its fundamentals. Days payable represents the average amount of days a company waits to pay its invoices from suppliers. View historical data on Capricor Therapeutics and its competitors. For the Biotechnology industry, the median Days Payable is 113.10 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Capricor Therapeutics's current Days Payable is 0.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.

Is Capricor Therapeutics stock overvalued right now?

Capricor Therapeutics (LTS:0HTB) has a current Days Payable of 0.00. The current Days Payable is 0.00. Capricor Therapeutics' overall GF Score™ is 37/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.

How is Days Payable calculated?

Days Payable is calculated from a company's financial statements. For Capricor Therapeutics (LTS:0HTB), the current Days Payable is 0.00 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Capricor Therapeutics Business Description

Industry Healthcare Biotechnology

Comparable Companies COAG DMRA MPLT MAZE AVBP NVAX AKTS ZBIO MLTX INBX VRTX REGN XBRU:UCB XBRU:ARGX XKRX:207940 ALNY ASX:CSL RVMD ONC MRNA

Other Exchanges CAPR:USA 4LN2:Germany

Address 10865 Road to the Cure, Suite 150, San Diego, CA, USA, 92121

Website https://www.capricor.com

Capricor Therapeutics Inc is a clinical-stage biotechnology company focused on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (DMD), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with high unmet medical needs. The company's product pipeline includes CAP-1002, deramiocel an allogeneic cardiac-derived cell therapy. Deramiocel is currently advancing through Phase 3 clinical development for the treatment of Duchenne muscular dystrophy. Through its proprietary StealthXTM platform, the group uses its exosome technology to conduct preclinical research focused on vaccinology, delivering oligonucleotides, proteins, and small molecules to treat.